The promise of C2, simulect, and certican in heart transplantation

Transplantation Proceedings

Volumn 36, Issue 2 SUPPL., 2004, Pages S504-S508

  Delgado, D H ^a   Ross, H J ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMITOTIC AGENT; AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CYCLOSPORIN A; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; STEROID;

AREA UNDER THE CURVE; CELL PROLIFERATION; CLINICAL TRIAL; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CYTOMEGALOVIRUS INFECTION; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MONITORING; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; GRAFT REJECTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART TRANSPLANTATION; HUMAN; IMMUNOTHERAPY; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MITOSIS INHIBITION; MORTALITY; NEPHROTOXICITY; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; TREATMENT OUTCOME; VASCULAR DISEASE;

EID: 1642370633     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2004.01.009     Document Type: Article

References (32)

1. Ross H., Hendry P., Dipchand A., et al. 2001 Canadian cardiovascular society consensus conference on cardiac transplantation. Can J Cardiol. 19:2003;620.
2. Hunt S.A. Current status of cardiac transplantation. JAMA. 280:1998;1692.
3. Ginns L., Cosimi A., Morris P. Immunosuppression in Transplantation. 1999;Blackwell Science, Massachusetts.
4. Valentine H. Neoral use in the cardiac transplant recipient. Transplant Proc. 32:2000;27S.
5. Kasiske B.L., Heim-Duthoy K., Venkateswara R., et al. The relationship between cyclosporine pharmacokinetic parameters and subsequent acute rejection in renal transplant patients. Transplantation. 46:1998;716.
6. Cole E.H. Neoral monitoring limitations of trough level monitoring and the potential role of limited sampling strategies. Transplant Proc. 32:2000;1556.
7. Mahalati K., Belitzky P., Sketris I., et al. Neoral monitoring by simplified sparse sampling area under the concentration-time curve its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. Transplantation. 68:1999;55.
8. Keon P., Landsberg D., Halloran P., et al. A randomized, prospective multicenter pharmacoepidemiologic study of cyclosporine microemulsion in stable renal graft recipients. Report of the Canadian neoral renal transplantation study group. Transplantation. 62:1996;1744.
9. Grant D., Kneteman N., Tchervenkov J., et al. Peak cyclosporine levels (Cmax) correlated with freedom from liver graft rejection results of a prospective, randomized comparison of neural and sandimmune for liver transplantation (NOF-8). Transplantation. 67:1999;1133.
10. Mahalati K., Belitsky P., Sketris I., et al. Neoral monitoring by simplified sparse sampling area under the concentration-time curve. Transplantation. 68:1999;55.
11. Levy G., Burra P., Cavallari A., et al. Improved clinical outcomes for liver transplant recipients using cyclosporine based on 2-hr post-dose levels (C2). Transplantation. 73:2002;840.
12. Levy G. Relationship of pharmacokinetics to clinical outcomes. Transplant Proc. 31:1999;1654.
13. Cantarovich M., Barkun J., Tchervenkov J., et al. Comparison of neoral dose monitoring with cyclosporine trough levels versus 2- hr postdose levels in stable liver transplant patients. Transplantation. 66:1998;1621.
14. Cantarovich M., Barkun J., Tchervenkov J., et al. Comparison of neoral dose monitoring with cyclosporine trough levels versus 2- hr postdose levels in stable liver transplant patients. Transplantation. 66:1998;1621.
15. Cantarovich M., Elstein E., Varennes B., et al. Clinical benefit of neural dose monitorin with cyclosporine 2-hr post-dose levels compared with trough levels in stable heart transplant patients. Transplantation. 68:1999;1839.
16. Cantarovich M., Besner J.G., Barkun J.S., et al. Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy. Clin Transplant. 12:1998;243.
17. Delgado D., Rao V., Cusimano R.J., et al. Monitoring of cyclosporine 2-hr post-dose and trough levels in heart transplantation. J Heart Lung Transp. 21:2002;102.
18. Carrier M., White M., Perrault L.P., et al. A 10-year experience with intravenous thymoglobulin in induction of immunosuppression following heart transplantation. J Heart Lung Transplant. 18:1999;1218.
19. Eisen H.J., Hobbs R.E., Davis S.F., et al. Safety, tolerability and efficacy of cyclosporine microemulsion in heart transplant recipients a randomized, multicenter, double-blind comparison with the oil based formulation of cyclosporine-results at six months after transplantation. Transplantation. 68:1999;663.
20. Kahan B.D., Rajagopalan P.R., Hall M. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-ionterleukin-2 receptor monoclonal antibody. United States Simulect Renal Study Group. Transplantation. 67:1999;276.
21. Sollinger H., Kaplan B., Pescovitz M.D., et al. Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection. Transplantation. 72:2001;1915.
22. Matl I., Bachleda P., Lao M., et al. Safety and efficacy of an alternative basiliximab (Simulect) regimen after renal transplantation administration of a single mf dose on the first postoperative day in patients receiving triple therapy with azathioprine. Transpl Int. 16:2003;45.
23. Lawn J.G., Davies E.A., Mouad G., et al. Randomized double-blind study of immunoprophylaxis with basiliximax, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation. Transplantation. 75:2003;37.
24. Crespo-Leiro M.G., Rodriguez-Lambert J.L., Segovia J.L., et al. Study of the safety and tolerability of Simulect® (basiliximab) versus OKT3 in heart transplantation. J Heart Lung Transplant. 22:2003;S141.
25. Kirklin J.K., Young J.B., McGiffin D.C. Heart transplantation. 2002;Churchill Livingstone, New York.
26. Delgado DH, Miriuka S, Cusimano RJ, et al: Use of basiliximab and cyclosporine in heart transplant patients with preoperative renal dysfunction. J Heart Lung Transplant (in press)
27. Schuler W., Sedrani R., Cottens S., et al. SDZ RAD, a new rapamycin derivative pharmacological properties in vitro and in vivo. Transplantation. 64:1997;36.
28. Schuurman H.J., Cottens S., Fuchs S., et al. SDZ RAD, new rapamycin derivative synergism with cyclosporine. Transplantation. 64:1997;32.
29. Neumayer H.H., Paradis K., Korn A., et al. Entry-into-human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipients. Br J Clin Pharmacol. 48:1999;69.
30. Kahan B.D., Kaplan B., Lorber M.I., et al. RAD in de novo renal transplantation comparison of three doses on the incidence and severity of acute rejection. Transplantation. 71:2001;1400.
31. Nikolova Z., Hof A., Baumlin Y., et al. Efficacy of SDZ RAD compared with CsA monotherapy and combined Rad/FTY720 treatment in a murine cardiac allotransplantation model. Transpl Immunol. 9:2001;43.
32. Eisen H.J., Tuzcu E.M., Dorent R., et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac transplant recipients. N Engl J Med. 349:2003;847.